Literature DB >> 26286017

Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus: an 11-year nationwide cohort study.

Chao-Han Lai1, Wu-Wei Lai1, Meng-Jiun Chiou2, Wei-Chieh Lin3, Yu-Jen Yang1, Chung-Yi Li4, Liang-Miin Tsai3.   

Abstract

OBJECTIVES: Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have an increased risk of developing coronary atherosclerosis. However, the impact of RA and SLE on the outcomes in patients undergoing percutaneous coronary intervention (PCI) remains largely underdetermined.
METHODS: Using the National Health Insurance Research Database of Taiwan, we identified 171 547 adult patients who underwent first-time PCI between 2000 and 2010. Among these patients, 525 had established RA, and 211 had SLE. The ORs of inhospital mortality and HRs of overall mortality and adverse cardiac outcomes after PCI (ie, ischaemic events, repeat revascularisation and major adverse cardiac events (MACE)) in relation to RA and SLE were estimated.
RESULTS: After adjustment for potential confounders, including patient characteristics and procedural variables, RA (OR=1.73, 95% CI 1.11 to 2.68) and SLE (OR=3.81, 95% CI 2.02 to 7.16) were independent predictors of inhospital mortality. In addition, RA was independently associated with overall mortality (HR=1.55, 95% CI 1.35 to 1.79), ischaemic events (HR=1.18, 95% CI 1.01 to 1.39) and MACE (HR=1.20, 95% CI 1.07 to 1.34) during long-term follow-up, whereas SLE was independently associated with overall mortality (HR=2.20, 95% CI 1.74 to 2.78), repeat revascularisation (HR=1.27, 95% CI 1.02 to 1.58) and MACE (HR=1.47, 95% CI 1.24 to 1.75). Compared with patients without autoimmune diseases, patients with more recent SLE-related hospitalisations prior to PCI were at higher risk of inhospital mortality (p for trend <0.0001).
CONCLUSIONS: This study recognises the inherent risks associated with RA and SLE in patients undergoing PCI and highlights the necessity to improve the caring and secondary prevention strategies for these high-risk patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Cardiovascular Disease; Outcomes research; Rheumatoid Arthritis; Systemic Lupus Erythematosus

Mesh:

Year:  2015        PMID: 26286017     DOI: 10.1136/annrheumdis-2015-207719

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  Kidney Stone History and Adverse Outcomes After Percutaneous Coronary Intervention.

Authors:  Chao-Han Lai; Li-Ching Huang; S Neil Holby; Ying-Ju Lai; Pei-Fang Su; Yu-Sheng Cheng; Yu Shyr; Ryan S Hsi
Journal:  Urology       Date:  2019-11-04       Impact factor: 2.649

2.  Outcomes of acute cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus: a population-based study.

Authors:  Chao-Han Lai; Cheng-Yang Hsieh; April Barnado; Li-Ching Huang; Sheau-Chiann Chen; Liang-Miin Tsai; Yu Shyr; Chung-Yi Li
Journal:  Rheumatology (Oxford)       Date:  2020-06-01       Impact factor: 7.580

3.  Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease.

Authors:  Marco Spartera; Cosmo Godino; Elena Baldissera; Corrado Campochiaro; Ketty La Spina; Patrizia Aiello; Anna Salerno; Michela Cera; Valeria Magni; Richard J Jabbour; Lorenzo Dagna; Moreno Tresoldi; Alberto Cappelletti; Ottavio Alfieri; Antonio Colombo; Maria Grazia Sabbadini; Alberto Margonato
Journal:  Am J Cardiovasc Dis       Date:  2017-02-15

Review 4.  Cardiovascular Outcomes in Systemic Lupus Erythematosus.

Authors:  Shrilekha Sairam; Amit Sureen; Jesus Gutierrez; The Q Dang; Kunal Mishra
Journal:  Curr Cardiol Rep       Date:  2022-01-13       Impact factor: 2.931

Review 5.  Assessment of Cardiac Risk in Women with Autoimmune Disease.

Authors:  Tyler Schmidt; Rekha Mankad
Journal:  Curr Cardiol Rep       Date:  2022-05-07       Impact factor: 3.955

Review 6.  Update on cardiovascular disease in lupus.

Authors:  Laura B Lewandowski; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

7.  Association of a Family History of Atrial Fibrillation With Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study.

Authors:  Shang-Hung Chang; Chang-Fu Kuo; I-Jun Chou; Lai-Chu See; Kuang-Hui Yu; Shue-Fen Luo; Lu-Hsiang Huang; Weiya Zhang; Michael Doherty; Ming-Shien Wen; Chi-Tai Kuo; Yung-Hsin Yeh
Journal:  JAMA Cardiol       Date:  2017-08-01       Impact factor: 14.676

8.  Blood pressure and albuminuria in a female mouse model of systemic lupus erythematosus: impact of long-term high salt consumption.

Authors:  Elena L Dent; Hanna J Broome; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-08-19       Impact factor: 3.619

Review 9.  Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.

Authors:  Pravesh Kumar Bundhun; Kamini Devi Boodhoo; Man-Yun Long; Meng-Hua Chen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

10.  Short- and Long-term Outcomes in Patients with Connective Tissue Diseases Undergoing Percutaneous Coronary Intervention.

Authors:  Li Zhou; Hui Chen; Wei-Ping Li; Hong-Li Gao; Dong-Bao Li; Hui-Qiang Zhao; Dao-Kuo Yao; Hong-Wei Li
Journal:  Chin Med J (Engl)       Date:  2016-04-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.